

**BURSOR & FISHER, P.A.**

L. Timothy Fisher (State Bar No. 191626)

Brittany S. Scott (State Bar No. 322946)

1990 North California Blvd., 9th Floor

Walnut Creek, CA 94596

Telephone: (925) 300-4455

Facsimile: (925) 407-2700

E-mail: ltfisher@bursor.com

bscott@bursor.com

*Attorneys for Plaintiff*

**UNITED STATES DISTRICT COURT  
NORTHERN DISTRICT OF CALIFORNIA**

ALISA BOURNE, individually and on behalf of  
all others similarly situated,

Plaintiff,

v.

CVS HEALTH CORPORATION and CVS  
PHARMACY, INC.,

Defendants.

Case No.

**CLASS ACTION COMPLAINT**

JURY TRIAL DEMANDED

1 Plaintiff Alisa Bourne (“Plaintiff”) brings this action on behalf of herself and all others  
2 similarly situated against Defendants CVS Health Corporation and CVS Pharmacy, Inc.  
3 (“Defendants” or “CVS”). Plaintiff makes the following allegations pursuant to the investigation  
4 of her counsel and based upon information and belief, except as to allegations specifically  
5 pertaining to herself which is based on personal knowledge.

6 **NATURE OF THE ACTION**

7 1. Plaintiff brings this class action on behalf of herself and similarly situated  
8 consumers who purchased CVS Health brand bandages (the “Bandages” or the “Products”).

9 2. Defendants’ Products are adhesive bandages that serve millions of people daily for  
10 the treatment of cuts, scrapes, and burns.

11 3. The Products’ packaging claims the bandages are “sterile” and “help prevent  
12 infection.” The packaging further instructs consumers that the Products are “for use on minor cuts  
13 and scrapes.” Many of the Products are also sold as “anti-bacterial” and state they “help prevent  
14 infection.” The only active ingredient listed for the antibacterial Bandages is Benzalkonium  
15 Chloride.

16 4. However, unbeknownst to consumers, the Products are unfit for their intended  
17 purpose because they contain PFAS, “forever chemicals,” which are dangerous to human health.

18 5. PFAS are a group of synthetic chemicals. Because PFAS persist and accumulate  
19 over time, they are harmful even at very low levels. Indeed, PFAS have been shown to have a  
20 number of toxicological effects in laboratory studies and have been associated with thyroid  
21 disorders, immunotoxic effects, and various cancers.

22 6. Furthermore, the Centers for Disease Control and Prevention (“CDC”) outlined a  
23 host of health effects associated with PFAS exposure, including liver damage, decreased fertility,  
24 and increased risk of asthma.

25 7. Accordingly, Plaintiff brings claims against Defendants individually and on behalf  
26 of a class of all others similarly situated for claims of breach of warranties, fraud, state consumer  
27 protection laws, and unjust enrichment.

**PARTIES**

1  
2 8. Plaintiff Alisa Bourne is, and at all times relevant to this action has been, a resident  
3 of Oakland, California. In or around 2023 and early 2024, Ms. Bourne purchased the following  
4 CVS Health brand bandages from a CVS store in California:

- 5 • CVS Health Assorted Antibacterial Bandages
- 6 • CVS Health Extra Large Flexible Fabric Antibacterial Bandages
- 7 • CVS Health Flexible Fabric Bandages
- 8 • CVS Health Children’s Antibacterial Bandages
- 9 • CVS Health Waterproof Antibacterial Bandages

10 9. When Ms. Bourne made her purchase, she believed that the Products were safe  
11 because they were intended to be used directly on skin for “use on minor cuts and scrapes” and are  
12 advertised as antibacterial, sterile, and can help prevent infection. Ms. Bourne’s belief was based  
13 on her review of the Products’ advertising and marketing, and she relied on Defendants’  
14 representations in making her purchase. Had Defendants disclosed on the label that the Products  
15 contained PFAS chemicals, and the harms that can result from contact with PFAS chemicals, she  
16 would not have purchased the Products, or at the very least, would have only been willing to pay  
17 significantly less. As a direct result of Defendants’ material misrepresentations and omissions, Ms.  
18 Bourne suffered, and continues to suffer, economic injuries. Ms. Bourne would consider  
19 purchasing Defendants’ Products in the future if Defendants removed the PFAS chemicals from  
20 them.

21 10. Defendant CVS Health Corporation is a Rhode Island corporation, with its principal  
22 executive offices located at One CVS Drive, Woonsocket, Rhode Island.

23 11. Defendant CVS Pharmacy, Inc. is a subsidiary of Defendant CVS Health  
24 Corporation, with its principal executive offices located at One CVS Drive, Woonsocket, Rhode  
25 Island.

26 12. Defendants own and operate pharmacy chain stores nationwide and have  
27 manufactured, marketed, and sold the Products nationwide in stores and online, including in  
28 California.

**JURISDICTION AND VENUE**

1  
2 13. This Court has subject matter jurisdiction pursuant to 28 U.S.C. § 1332(d)(2)(A).  
3 There are more than 100 Class Members, the aggregate claims of all members of the proposed  
4 Class exceed \$5,000,000.00, exclusive of interest and costs, and at least one Class Member is a  
5 citizen of a state different than Defendant.

6 14. Defendants are a corporation under the Class Action Fairness Act of 2005  
7 (“CAFA”), 28 U.S.C. § 1332(d), and therefore are citizens of Rhode Island because Defendants  
8 have its principal place of business in the State of Rhode Island.

9 15. This Court has personal jurisdiction over Defendants because Defendants  
10 purposefully availed themselves to the benefits of the forum, and because a substantial portion of  
11 the events giving rise to this complaint occurred in this District.

12 16. Venue is proper in this District pursuant to 28 U.S.C. § 1391 because this District is  
13 where a substantial part of the conduct giving rise to Plaintiff’s claims occurred.

**FACTUAL ALLEGATIONS**

14  
15 **I. The Products and Defendants’ Marketing**

16 17. Defendants market and sell waterproof, antibacterial, and fabric bandages of various  
17 sizes under their brand name CVS Health in CVS stores and online.

18 18. The Products are adhesive to human skin and are intended for “use on minor cuts  
19 and scrapes.” Each bandage has adhesive flaps with an absorbent pad in the center that serves as a  
20 cushion for cuts, scrapes, and other injuries to the skin.

21 19. According to the packaging for Defendants’ antibacterial bandages, the Products are  
22 “sterile,” “resist bacteria,” and “helps prevent infection.” The back of the packaging explains that  
23 “Benzalkonium chloride in the dressing helps fight against bacteria & infection.”  
24  
25  
26  
27  
28

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

**CVS Health** Active Use

**Extra Large Flexible Fabric**

**ANTIBACTERIAL BANDAGES**

Helps prevent infection

- Resists bacteria\*
- Highly absorbent
- Pain-free pad†

**Breathable material**

**STERILE**  
Actual Product Size on Back Panel

**10**  
EXTRA LARGE  
2 IN x 4 IN (50 mm x 101 mm)

TRIPLE LAYER PROTECTION

The packaging features a blue background with a white bandage illustration. A yellow banner at the top right says 'Active Use'. A heart-shaped graphic shows two hands shaking. A circular seal at the bottom right highlights 'TRIPLE LAYER PROTECTION'.

**CVS Health**

**Antibacterial agent**  
Benzalkonium chloride in the dressing helps fight against bacteria & infection.

**Highly absorbent pad**  
Absorbs more fluid than most comparable bandages.


**Pain-free pad**  
Gentle, non-stick pad protects wound from disruption & tearing.

**TRIPLE LAYER PROTECTION**

**Actual Size (10)**  
2 IN x 4 IN  
(50 mm x 101 mm)

The packaging shows a detailed view of the bandage with callout lines pointing to the antibacterial agent, absorbent pad, and pain-free pad. A circular seal at the bottom right highlights 'TRIPLE LAYER PROTECTION'.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28



20. Defendants' waterproof antibacterial bandages make similar claims.



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28




**CVS Health**

**Pain-free pad**  
Gentle, non-stick pad protects wound from disruption and tearing.

**Antibacterial agent**  
Benzalkonium chloride kills bacteria within the pad\* and helps prevent infection.

**Highly absorbent pad**  
Innovative pad technology absorbs more fluid than most leading bandages.

\*This product is not manufactured or distributed by Johnson & Johnson, owner of the trademarks Band-Aid® and Water Block®. Compare to Band-Aid® Water Block® in overall performance and quality. Band-Aid® does not contain Benzalkonium Chloride. \*Based on laboratory testing.



**CVS Health**

For use on minor cuts, scrapes and burns.

**Directions:**  
For optimal results, apply bandage to clean, dry skin. Change dressing daily, or more often if needed.  
Single use.

**Warning:**  
For external use only. Do not use in the eyes or apply over large areas of the body. In case of deep cuts, puncture wounds, animal bites or serious burns, consult a doctor. Stop use and consult a doctor if the condition persists or gets worse. Do not use longer than one week unless directed by a doctor. Keep this and all drugs out of the reach of children.

**Active Ingredient:**  
Benzalkonium Chloride  
0.1%

Not made with natural rubber latex.  
Sterile unless wrapper is opened or damaged.

21. The Products also list a single active ingredient – Benzalkonium chloride.



1           22. Reasonable consumers purchased and continue to purchase Defendants’ Products  
2 under the reasonable belief that they do not contain the synthetic chemicals, PFAS, that could  
3 adversely impact their health or the health of their children.

4 **II. PFAS in Defendants’ Products.**

5           23. Defendants’ Products pose a health and safety risk due to the presence of PFAS in  
6 the Products.

7           24. Mamavation is a consumer “watchdog” community group, which provides “eco-  
8 wellness product investigations for moms.”

9           25. To enable consumers to avoid the harms associated with PFAS chemicals,  
10 Mamavation has commissioned consumer studies on numerous beauty and personal care products,  
11 foods and beverages, supplements, menstrual products, clothing, food packaging and parchment  
12 paper, baby and children products, electronic equipment, and cleaning and laundry products.

13           26. Because of known toxicity associated with PFAS, Mamavation commissioned  
14 scientific studies on indications of PFAS in bandages, to analyze popular bandages marketed to  
15 consumers.

16           27. To conduct the studies, bandages were purchased and donated from Mamavation  
17 community members between November 2022 and February 2024 from Walmart, CVS, Rite Aid,  
18 Target, and Amazon. Each of the products tested was recorded in Mamavation’s database and then  
19 sent directly to the lab within the product’s original packaging.

20           28. Mamavation sent 40 bandages from 18 brands for testing at an EPA-certified  
21 laboratory, including Defendants’ bandages.

22           29. Mamavation’s EPA-certified laboratory uses marker testing to identify the potential  
23 presence of PFAS chemicals in bandages. Organic fluorine is a marker for PFAS because all PFAS  
24 are carbon-based compounds that contain fluorine. The specific laboratory method used to test for  
25 total fluorine was the Determination of Total Fluorine by Oxygen Flask Combustion and  
26 IonSelective Electrode. If total fluorine was observed at a detection level of 10 ppm or greater, the  
27 laboratory did the Determination of free Fluoride Ion in the product by Ion-Selective Electrode and  
28 then subtracted that from the Total Fluorine to determine the amount of organic fluorine. This



1 marker testing is likely to show the presence of PFAS. Organic fluorine can also capture other  
2 fluoropolymers, pharmaceuticals, and common hydrofluorocarbon refrigerants, such as 1,1,1,2-  
3 tetrafluoroethane (commonly known as R-134a) and 2,3,3,3-tetrafluoropropene (commonly known  
4 as HFO-1234yf), which are all also PFAS chemicals.

5 30. Total organic fluorine analysis is used to detect organic fluorine, which is the  
6 foundational element (and defining characteristic) of PFAS chemicals.

7 31. In the context of chemistry, the term “organic” refers to compounds containing  
8 carbon. Organic fluorine is created by the chemical bond between carbon atoms and fluorine  
9 atoms. The strong bond created between carbon and fluorine is what defines PFAS chemicals and  
10 is the reason for their common usage.

11 32. Total organic fluorine testing is critical to the detection of the 99.99% of PFAS that  
12 cannot be detected through limited targeted testing. Because organic fluorine is the identifying  
13 element of PFAS chemicals and is present in all PFAS varieties, the detection of organic fluorine in  
14 a sample necessarily means that PFAS chemicals are present in some form.

15 33. It is nearly impossible for total organic fluorine testing to yield a false positive  
16 detection of PFAS in a sample. Total organic fluorine testing only measure fluorine that originates  
17 from a substance where fluorine is attached to a carbon backbone. Therefore, total organic fluorine  
18 testing does not detect any other forms of fluorine, such as inorganic fluorine (i.e., fluoride).

19 34. Organic fluorine is not naturally present in the human body, and is practically  
20 nonexistent outside of its use in man-made PFAS chemicals.

21 35. In light of the limitations of targeted testing, total organic fluorine testing is the  
22 only method that is able to reliably detect the presence or absence of the thousands of varieties of  
23 PFAS chemicals for which targeted testing is not currently available.

24 36. Consequently, total organic fluorine testing is widely accepted by scientists,  
25 researchers, and regulators as the reliable method to detect a PFAS chemical in a sample.

26 37. According to Scott Belcher, Ph.D. & Associate Professor with the Center for  
27 Environmental & Health Effects of PFAS at North Carolina State University, “fluoropolymers,  
28 such as polytetrafluoroethylene (PTFE), are extremely common forms of PFAS that could be

1 contributing to the organic fluorine found in bandages. Methods used for detecting individual  
2 PFAS, such as PFOA or GenX, cannot directly identify PTFE. However, the analysis of total  
3 organic fluorine (TOF) does account for all PFAS contaminants in bandages, including PTFE.  
4 Therefore, this method of testing serves as a good ‘spot-check’ of consumer products.”

5 38. Mamavation’s testing of Defendants’ Bandages produced the following results:

- 6 • CVS Health C60 Flexible Fabric Antibacterial Bandages — 201 ppm organic  
7 fluorine on the absorbent pad.
- 8 • CVS Health C70 Flexible Fabric Sterile Bandages —272 ppm organic fluorine  
9 on the sticky flaps.
- 10 • CVS Health C80 Flexible Fabric Antibacterial Bandages — 128 ppm organic  
11 fluorine in the absorbent pad.
- 12 • CVS Health Waterproof Adhesive Bandages — 20 ppm organic fluorine on the  
13 sticky flaps.

14 39. In response to the results of the studies, Linda Birnbaum, Scientist Emeritus and  
15 Former Director of the National Institute of Environmental Health Sciences and National  
16 Toxicology Program & Scholar in Residence at Duke University stated: “Because bandages are  
17 placed upon open wounds, it’s troubling to learn that they may also be exposing children and adults  
18 to PFAS. It’s obvious from the data that PFAS are not needed for wound care, so it’s important that  
19 the industry remove their presence to protect the public from PFAS and opt instead for PFAS-free  
20 materials.”

21 40. Moreover, Plaintiff’s counsel conducted testing on some of Plaintiff’s Products  
22 through a certified lab, which confirmed the presence of PFAS in Plaintiff’s Products:

- 23 • CVS Health XL Flexible Fabric Antibacterial Bandages — 216 ppm organic  
24 fluorine on the sticky flaps.
- 25 • CVS Health Flexible Fabric Antibacterial Bandages — 199 ppm organic  
26 fluorine on the sticky flaps.

27 41. These test results indicate the presence of PFAS in all of Defendants’ Products.  
28

1 **III. PFAS Chemicals Are Harmful to Humans**

2 42. According to the Agency for Toxic Substances and Disease Registry, PFAS  
3 chemicals “are man-made chemicals that have been used in industry and consumer products  
4 worldwide since the 1940s. They have been used to make nonstick cookware, water-repellent  
5 clothing, stain resistant fabrics and carpets, some cosmetics, some firefighting foams, and products  
6 that resist grease, water, and oil.”

7 43. One common characteristic of concern in regard to PFAS is that many types break  
8 down very slowly and can build up in people, animals, and the environment over time. In fact, all  
9 PFAS contain carbon-fluorine bonds—one of the strongest in nature—making them highly  
10 persistent in the environment and our bodies.

11 44. Consequently, PFAS chemicals are often referred to as “forever chemicals.”

12 45. PFAS are often divided into two groups: long chain and short chain, both of which  
13 break down slowly, if at all. In fact, long chain PFAS have been banned in the European Union and  
14 phased out by major U.S. manufacturers due to their health risks. Regardless of length, research  
15 from the U.S. National Toxicology Program suggests that both long chain and short chain PFAS  
16 have similar levels of toxicity.

17 46. PFAS chemicals have been connected with severe and lingering health  
18 consequences. Erika Schreder, Director of Science at Toxic-Free Future, and Jennifer Dickman,  
19 Senior Program Associate of Safer Chemicals, Healthy Families, have explained that “[p]rimary  
20 among [PFAS-linked health concerns] are cancer and effects on lipid metabolism, but they also  
21 include immune suppression, thyroid disease, and harm to reproduction.”

22 47. Similarly, Dr. Lina S. Birnbaum, stated that “[t]hese toxic chemicals are linked to  
23 serious problems like cancer, liver damage, decreased fertility, and asthma. ... PFAS can [also]  
24 weaken our immune system, making us more vulnerable to infectious diseases like COVID-19.”

25 48. In children, PFAS has also been linked to “[l]ower antibody response[s] to some  
26 vaccines,” thereby rendering children more vulnerable to disease they would otherwise be immune  
27 from.

1           49.     Significantly, a study conducted by the National Institute for Occupational Safety  
2 and Health found that “dermal exposure to PFOA is immunotoxic and raise concern about potential  
3 adverse effects from dermal exposure.”

4           50.     PFAS chemicals can be harmful at extremely low levels of exposure. According to  
5 the EPA, the levels at which negative human health effects could occur are significantly lower than  
6 previously understood, including at near zero in some instances.

7           51.     In other words, there is no “safe” level of exposure to PFAS chemicals. Even  
8 “trace” levels of PFAS can be harmful to human health.

9           52.     There is no effective treatment for removal of PFAS chemicals from the body.  
10 Therefore, experts agree that the most effective strategy to decrease health risk is to avoid and/or  
11 limit exposure to products known to contain PFAS chemicals.

12           53.     Only in recent years has the presence of PFAS used in consumer products, and their  
13 consequent risks, begun to be publicized and discussed in the media and scientific literature. Based  
14 on this newly available information, consumers are rightfully concerned about the presence or risk  
15 of PFAS in various consumer products.

16           54.     In June 2022, the EPA announced a lifetime health advisory related to PFAS. A  
17 health advisory is not a binding regulation but serves as “informal technical guidance to assist  
18 government officials.” The June 2022 advisory sets lifetime health advisory levels for PFOA at  
19 0.004 parts per trillion (ppt) and PFOS at 0.02 ppt. These levels are below the detection capability  
20 of most measurement devices, meaning that EPA considers any detection of PFOA or PFOS to  
21 exceed the lifetime health advisory level.

22           55.     On April 10, 2024, the Biden Administration issued the first-ever national, legally  
23 enforceable drinking water standard to protect communities from exposure to PFAS. The standards  
24 set a maximum contaminant level of 4 parts per trillion for PFOA and PFOS individually. For other  
25 forms of PFAS, the maximum set by the Administration is 10 parts per trillion.

26           56.     Moreover, for PFOA and PFOS, the EPA is setting a Maximum Contaminant Level  
27 health-based goal at zero. This is reflective of the latest science supporting that there is no level of  
28 exposure to PFAS without risk of health impacts, including several cancers.

1           57. For context, 10 parts per trillion equates to .0001 parts per million. This means that  
2 the PFAS found in Defendants' Bandages of up to 256 parts per million goes well beyond the  
3 limitations set forth by the government on drinking water.

4 **IV. Defendants' Misrepresentations And Omissions Are Actionable**

5           58. Plaintiff and Class Members would not have purchased the Products on the same  
6 terms had they known the truth about the Product.

7           59. Nowhere on the Products packaging or labels do Defendants disclose the presence  
8 of PFAS. Reasonable consumers would believe the Products to be free of harmful toxins.

9           60. Plaintiff and Class Members bargained for bandages that were free of harmful  
10 toxins, and were deprived of the basis of their bargain when Defendants sold them a Product  
11 containing PFAS.

12           61. Accordingly, Plaintiff and Class Members suffered economic injuries as a result of  
13 purchasing the Product.

14           62. Moreover, because these facts relate to a critical safety-related deficiency in the  
15 Products, Defendants were under a continuous duty to disclose to Plaintiff and Class Members the  
16 true standard, quality, and grade of the Products and to disclose that the Products may contain  
17 substances known to have adverse health effects. Defendants, as manufacturers or parties to a  
18 contract to manufacture, thereby providing and approving designs of the Products, and as sellers  
19 and advertisers of the Products, is best situated to know the content of its Products. Nonetheless,  
20 Defendants concealed and affirmatively misrepresented the true nature of the Products, as  
21 discussed herein.

22           63. Consumers lack the expertise to ascertain the true ingredients in the adhesive  
23 bandages prior to purchase.

24           64. Absent testing by a qualified lab, consumers such as Plaintiff and the Class  
25 Members were unable to determine that Defendants' Bandages contained PFAS chemicals given  
26 Defendants' failure to disclose the presence of PFAS.

27           65. Accordingly, reasonable consumers must, and do, rely on Defendants to accurately  
28 and honestly advertise their products' ingredients and benefits. Further, consumers rely on

1 Defendants to not contradict those representations by using artificial chemicals in their adhesive  
2 bandages that are known to pose a risk to human health. Such misrepresentations are material to  
3 reasonable consumers' purchasing decisions.

4 66. Consumer reliance upon Defendants' representations and omissions were reasonable  
5 and foreseeable. It is beyond reasonable dispute that the presence of harmful chemicals in adhesive  
6 bandages is material to reasonable consumers.

7 67. Defendants had exclusive knowledge of the contents and ingredients of its  
8 Bandages, including whether the products contained PFAS chemicals.

9 68. Defendants also had exclusive knowledge of its ingredient suppliers and obtained or  
10 could have obtained information from their suppliers about the contents and ingredients to the  
11 Bandages, including whether they contained PFAS chemicals.

12 69. Likewise, Defendants are in the best position to know what content it placed on its  
13 website and in marketing materials during the relevant timeframe.

14 70. Defendants' false statements, misleading, and material omissions are intentional  
15 and careless, and render their adhesive bandages worthless or less valuable.

16 71. Had Defendants disclosed to Plaintiff and Class Members that their Bandages  
17 contained and contain PFAS chemicals, or risked containing PFAS, Plaintiff and Class Members  
18 would not have purchased Defendants' Bandages, or they would have paid significantly less for  
19 them.

20 72. Plaintiff and Class Members were among the intended recipients of Defendants'  
21 deceptive representations and omissions described herein.

22 73. Defendants' representations and omissions, as described herein, are material in that  
23 a reasonable person would attach importance to such information and would be induced to act upon  
24 such information in making purchase decisions, especially for a consumer health product such as a  
25 bandage.

26 74. In making the false, misleading, and deceptive representations, Defendants knew  
27 and intended consumers would pay a premium for their adhesive bandage products that are made  
28

1 from or contain synthetic or artificial chemical ingredients that are known to be harmful to humans  
2 and the environment.

3 75. This is evidenced by the Products packaging, which states “not made with natural  
4 rubber latex,” clearly as an appeal to consumer preference on ingredients of their products.

5 76. A reasonable consumer would not expect dangerous and health threatening  
6 chemicals to be in a bandage claimed to be made from fabric, are antibacterial and sterile, and  
7 intended to be used to protect cuts and scrapes.

8 77. Plaintiff and Class Members paid money for Defendants’ Bandages, and paid a  
9 premium for an expected quality. However, Plaintiff and Class Members did not obtain the full  
10 value of the Products due to Defendants’ misrepresentations as described herein.

11 78. Plaintiff and Class Members purchased, purchased more of, or paid more for,  
12 Defendants’ Bandages than they would have had they known the truth about the Products’ harmful  
13 ingredients. Accordingly, Plaintiff and Class Members have suffered injury in fact and lost money  
14 or property as a result of Defendants’ wrongful conduct.

15 **CLASS ALLEGATIONS**

16 79. ***Nationwide Class.*** Plaintiff brings this nationwide class action pursuant to rules  
17 23(b)(2), 23(b)(3), and 23(c)(4) of the Federal Rules of Civil Procedure, individually and on behalf  
18 of a class defined as:

19 All persons in the United States who purchased the Products during the  
20 statute of limitations period (the “Class”).

21 80. Excluded from the Class are: (1) persons who made such purchases for purposes of  
22 resale; (2) any Judge or Magistrate presiding over this action and any members of their families;  
23 (3) Defendants, Defendants’ subsidiaries, parents, successors, predecessors, and any entity in  
24 which Defendants or its parent has a controlling interest and their current or former employees,  
25 officers, and directors; and (4) Plaintiff’s counsel and Defense counsel.

26 81. ***California Subclass.*** Plaintiff also seeks to represent a subclass of:

27 All persons who purchased the Products in the State of California during  
28 the statute of limitations period (the “California Subclass”).



1           82. Excluded from the California Subclass are: (1) persons who made such purchases  
2 for purpose of resale; (2) any Judge or Magistrate presiding over this action and any members of  
3 their families; (3) Defendants, Defendants’ subsidiaries, parents, successors, predecessors, and any  
4 entity in which Defendants or its parent has a controlling interest and their current or former  
5 employees, officers, and directors; and (4) Plaintiff’s counsel and Defense counsel.

6           83. As a result of additional information obtained through further investigation and  
7 discovery, the above-described Class and Subclass may be modified or narrowed as appropriate.

8           84. **Numerosity.** At this time, Plaintiff does not know the exact number of members of  
9 the aforementioned Class and Subclass (“Class Members” or “Subclass Members”). However,  
10 given the nature of the claims, Plaintiff believes that Class and Subclass Members are so numerous  
11 that joinder of all members is impracticable.

12           85. **Commonality and Predominance.** There is a well-defined community of interest in  
13 the questions of law and facts involved in this case. Questions of law and fact common to  
14 members of the Class that predominate over questions that may affect individual Class Members  
15 include:

- 16           • Whether the Products contain PFAS;
- 17           • Whether Defendants misrepresented and/or failed to disclose  
18           material facts concerning the Products;
- 19           • Whether Defendants had a duty to disclose the presence of PFAS in  
20           its Products;
- 21           • Whether the Products posed a health risk to consumers;
- 22           • Whether Defendants’ conduct was unlawful;
- 23           • Whether Defendants have been unjustly enriched as a result of the  
24           unlawful conduct alleged in this Complaint such that it would be  
25           inequitable for Defendants to retain the benefits conferred upon it  
26           by Plaintiff and the Class;
- 27           • Whether Plaintiff and the Class sustained damages with respect to  
28           the common law claims asserted, and if so, the proper measure for  
              their damages.

26           86. With respect to the California Subclass, additional questions of law and fact  
27 common to the members include whether Defendants violated California Commercial Code §  
28

1 2314; California Civil Code § 1790. *et seq.* Song-Beverly Consumer Warranty Act; Business &  
2 Professions Code § 17500, *et seq.*, California’s False Advertising Law; and Business & Professions  
3 Code § 17200, *et seq.*, California’s Unfair Competition Law.

4 87. **Typicality.** The claims of the named Plaintiff are typical of the claims of the Classes  
5 because the named Plaintiff, like other members of the Classes, purchased the Products, relying on  
6 the representations and warranties made by Defendants on its packaging and online that the  
7 Products were safe and did not contain harmful chemicals.

8 88. **Adequate Representation.** Plaintiff is an adequate representative of the Class and  
9 California Subclass because her interests do not conflict with the interests of the Class Members  
10 she seeks to represent, she has retained competent counsel experienced in prosecuting class actions,  
11 and she intends to prosecute this action vigorously. The interests of the Class Members will be  
12 fairly and adequately protected by Plaintiff and her counsel.

13 89. **Superiority.** The class mechanism is superior to other available means for the fair  
14 and efficient adjudication of the claims of Class Members. Each individual Class Member may  
15 lack the resources to undergo the burden and expense of individual prosecution of the complex and  
16 extensive litigation necessary to establish Defendants’ liability. Individualized litigation increases  
17 the delay and expense to all parties and multiplies the burden on the judicial system presented by  
18 the complex legal and factual issues of this case. Individualized litigation also presents a potential  
19 for inconsistent or contradictory judgments. In contrast, the class action device presents far fewer  
20 management difficulties and provides the benefits of single adjudication, economy of scale, and  
21 comprehensive supervision by a single court on the issue of Defendants’ liability. Class treatment  
22 of the liability issues will ensure that all claims and claimants are before this Court for consistent  
23 adjudication of liability issues.

24 **CAUSES OF ACTION**

25 **COUNT I**

26 **Violation of California’s Unfair Competition Law,  
27 California Business & Professions Code § 17200, *et seq.*  
(On Behalf Of The California Subclass)**

28 90. Plaintiff incorporates the foregoing allegations as if fully set forth herein.

1           91. Plaintiff brings this claim individually and on behalf of the California Subclass  
2 against Defendants.

3           92. California Business and Professions Code § 17200 prohibits “any unlawful, unfair,  
4 or fraudulent business act or practice.” For the reasons discussed above, Defendants have engaged  
5 in unlawful, unfair, and fraudulent business acts or practices in violation of California Business &  
6 Professions Code § 17200.

7           93. By committing the acts and practices alleged herein, Defendants have violated  
8 California’s Unfair Competition Law (“UCL”), Cal. Bus. & Prof. Code §§ 17200-17210, as to the  
9 California Subclass, by engaging in unlawful, fraudulent, and unfair conduct.

10           94. Defendants have violated the UCL’s proscription against engaging in **Unlawful**  
11 **Business Practices** because of their violations of California’s Song-Beverly Act, and violations of  
12 California’s False Advertising Law, in addition to breach of warranty and violations of common  
13 law.

14           95. As more fully described above, Defendants’ misleading marketing, advertising,  
15 packaging, and labeling of the Products is likely to deceive reasonable consumers. In addition,  
16 Defendants have committed unlawful business practices by, inter alia, making the representations  
17 and omissions of material facts, as set forth more fully herein, and violating the common law.

18           96. Plaintiff and the California Subclass Members reserve the right to allege other  
19 violations of law which constitute other unlawful business acts or practices.

20           97. Defendants have also violated the UCL’s proscription against engaging in **Unfair**  
21 **Business Practices**. Defendants’ acts, omissions, misrepresentations, practices and non-  
22 disclosures as alleged herein also constitute “unfair” business acts and practices within the meaning  
23 of Business & Professions Code § 17200 *et seq.* in that their conduct is substantially injurious to  
24 consumers, offends public policy, and is immoral, unethical, oppressive, and unscrupulous as the  
25 gravity of the conduct outweighs any alleged benefits attributable to such conduct.

26           98. There were reasonably available alternatives to further Defendants’ legitimate  
27 business interests, other than the conduct described herein.

28

1 99. Defendants have further violated the UCL’s proscription against engaging in  
2 **Fraudulent Business Practices**. Defendants’ claims, nondisclosures, and misleading statements  
3 with respect to the Products, as more fully set forth above, were false, misleading and/or likely to  
4 deceive the consuming public within the meaning of Business & Professions Code § 17200.

5 100. Plaintiff and the other California Subclass Members suffered a substantial injury by  
6 virtue of buying the Products that they would not have purchased, or paying more than they  
7 otherwise would have for the Products, absent Defendants’ unlawful, fraudulent, and unfair  
8 marketing, advertising, packaging, and omission about the defective nature of the Products.

9 101. There is no benefit to consumers or competition from deceptively marketing and  
10 omitting materials facts about the true nature of the Products.

11 102. Plaintiff and the other California Subclass Members had no way of reasonably  
12 knowing that the Products they purchased were not as marketed, advertised, packaged, or labeled.  
13 Thus, they could not have reasonably avoided the injury each of them suffered.

14 103. The gravity of the consequences of Defendants’ conduct as described outweighs any  
15 justification, motive, or reason therefore, particularly considering the available legal alternatives  
16 which exist in the marketplace, and such conduct is immoral, unethical, unscrupulous, offends  
17 established public policy, or is substantially injurious to Plaintiff and the other California Subclass  
18 Members.

19 104. Pursuant to California Business and Professional Code § 17203, Plaintiff and the  
20 California Subclass seek an order of this Court that includes, but is not limited to, requiring  
21 Defendants to (a) provide restitution to Plaintiff and the other California Subclass Members; (b)  
22 disgorge all revenues obtained as a result of violations of the UCL; and (c) pay Plaintiff and the  
23 California Subclass’s attorneys’ fees and costs.

24 **COUNT II**  
25 **Violation of California’s False Advertising Law (“FAL”)**  
26 **California Bus. & Prof. Code § 17500, *et seq.***  
27 **(On Behalf Of The California Subclass)**

28 105. Plaintiff incorporates the foregoing allegations as if fully set forth herein.

1           106. Plaintiff brings this claim individually and on behalf of the California Subclass  
2 against Defendants.

3           107. Defendants' acts and practices, as described herein, have deceived and/or are likely  
4 to continue to deceive California Subclass Members and the public. As described above, and  
5 throughout this Complaint, Defendants misrepresented the Products as preventing infection,  
6 antibacterial, and sterile when in fact, the Products were not safe because of the inclusion of PFAS  
7 chemicals.

8           108. By its actions, Defendants disseminated uniform advertising regarding the Products  
9 to and across California. The advertising was, by its very nature, unfair, deceptive, untrue, and  
10 misleading within the meaning of California Business & Professions Code § 17500, *et seq.* Such  
11 advertisements were intended to and likely did deceive the consuming public for the reasons  
12 detailed herein.

13           109. The above-described false, misleading, and deceptive advertising Defendants  
14 disseminated continues to have a likelihood to deceive in that Defendants failed to disclose that the  
15 Products contains substances that pose a significant risk to the health and well-being of Plaintiff  
16 and the California Subclass Members.

17           110. Defendants continue to misrepresent to consumers that the Products are safe for its  
18 intended use and are antibacterial and help prevent infection. However, as described, that is not the  
19 case.

20           111. In making and disseminating these statements, Defendants knew, or should have  
21 known, its advertisements were untrue and misleading in violation of California law. Plaintiff and  
22 other California Subclass Members based their purchasing decisions on Defendants'  
23 misrepresentation and omissions of material facts. Plaintiff and California Subclass Members were  
24 injured in fact and lost money and property as a result.

25           112. The misrepresentations and non-disclosures by Defendants of the material facts  
26 described and detailed herein constitute false and misleading advertising and, therefore, constitute a  
27 violation of California Business & Professions Code § 17500, *et seq.*  
28



1 particular purpose and that the buyer is relying on the manufacturer’s or retailer’s skill or judgment  
2 to furnish suitable goods consistent with that represented purpose.

3 119. The Products at issue here fall under “consumer goods” within the meaning of  
4 California Civil Code § 1791(a).

5 120. Plaintiff and the California Class Members who purchased the Products are “retail  
6 buyers” within the meaning of California Civil Code § 1791.

7 121. Defendants are in the business of manufacturing, assembling, and/or producing the  
8 Products and/or selling the Products to retail buyers, and therefore are a “manufacturer” and  
9 “seller” within the meaning of California Civil Code § 1791.

10 122. Defendants impliedly warranted to retailer buyers that the Products were  
11 merchantable in that they would: (a) pass without objection in the trade or industry under the  
12 contract description, and (b) were fit for the ordinary purposes for which the Products are used.

13 For a consumer good to be “merchantable” under the Act, it must satisfy both elements.

14 Defendants breached these implied warranties because the Products are unsafe. Therefore, the  
15 Products would not pass without objection in the trade or industry and is not fit for the ordinary  
16 purpose for which it is used.

17 123. Plaintiff and California Subclass Members purchased the Products in reliance upon  
18 Defendants’ skill and judgment in properly packaging, labeling, and marketing the Products.

19 124. The Products were defective at the time of sale when they were under the exclusive  
20 control of Defendants. The issues described in this complaint were latent in the Products and not  
21 reasonably discoverable at the time of sale.

22 125. Defendants knew that the Products would be purchased and used without additional  
23 testing by Plaintiff and California Subclass Members.

24 126. As a direct and proximate cause of Defendants’ breach of the implied warranty,  
25 Plaintiff and California Subclass Members have been injured and harmed because they would not  
26 have purchased the Products if they knew the truth about the Products, namely, that they are unfit  
27 for use and posed a significant safety risk.

28





**COUNT V**  
**Fraudulent Concealment**  
**(On Behalf Of The Nationwide Class)**

1  
2  
3 135. Plaintiff incorporates the foregoing allegations as if fully set forth herein.

4 136. Plaintiff brings this claim individually and on behalf of the Nationwide Class.

5 137. Defendants concealed and failed to disclose on the Products packaging and labeling  
6 the material fact that the bandages contained or risked containing PFAS, and that the bandages  
7 were not safe or healthy for use.

8 138. As discussed at great length above, it has been widely publicized that PFAS are  
9 harmful chemicals to humans, animals, and the environment. The EPA, CDC and many other  
10 groups and publications have reported on the potential risks and dangers of PFAS chemicals.  
11 Accordingly, Defendants knew or should have known that PFAS are dangerous, and concealing  
12 this known fact is detrimental to the consumer.

13 139. Defendants have a duty to disclose that the bandages contained or risked containing  
14 PFAS; however, Defendants did not make this disclosure.

15 140. Plaintiff and the Class Members all paid a premium for the Products based upon the  
16 way the Products are represented, which did not include the inclusion of PFAS. Products that are  
17 tainted with PFAS are not worth a premium to a reasonable consumer.

18 141. Defendants had superior knowledge or means of knowledge available to them and  
19 knew that Plaintiff and Class Members would rely upon the representations and omissions of  
20 Defendants regarding the quality and ingredients of its bandages. Consumers lack the meaningful  
21 ability to test or independently ascertain or verify whether a product contains PFAS, especially at  
22 the point of sale.

23 142. Defendants' concealment was material and intentional because people are  
24 concerned with what is in the products that they are putting onto and into their bodies. Consumers  
25 such as Plaintiff and the Class Members are influenced by the ingredients and contents listed, as  
26 well as any warnings (or lack thereof) on the products they buy. Defendants know that if they had  
27 not omitted that the Products contained or risked containing PFAS, then Plaintiff and the Class  
28

1 Members would not have agreed to pay a premium price for the Products, or would not have  
2 purchased the Products at all; however, Defendants wanted to increase sales and profits.

3 143. Defendants' concealment misled Plaintiff and the Class Members as to the true  
4 nature of what they were buying and putting onto their and their family's bodies.

5 144. Defendants fraudulently concealed that the Products contained or risked containing  
6 PFAS. Consequently, Plaintiff and the other members of the Class have suffered injury and are  
7 entitled to damages in an amount to be proven at trial.

8 145. Defendants had a duty to Plaintiff and the Nationwide Class to exercise reasonable  
9 and ordinary care in the developing, testing, manufacture, marketing, detailing, distribution, and  
10 sale of the Products.

11 **COUNT VI**  
12 **Unjust Enrichment**  
13 **(On Behalf Of The Nationwide Class)**

14 146. Plaintiff incorporates the foregoing allegations as if fully set forth herein.

15 147. Plaintiff brings this claim individually and on behalf of the Nationwide Class.

16 148. To the extent required by law, this cause of action is alleged in the alternative to  
17 legal claims, as permitted under Fed. R. Civ. P. 8.

18 149. Plaintiff and the Nationwide Class Members conferred benefits on Defendants by  
19 purchasing the Products.

20 150. Defendants were unjustly enriched in retaining the revenues derived from Plaintiff  
21 and the Nationwide Class Members' purchases of the Products. Retention of those monies under  
22 these circumstances is unjust and inequitable because Defendants misrepresented and failed to  
23 disclose that the Products were unfit for their intended purpose as it was not safe for use. These  
24 omissions and misrepresentations caused injuries to Plaintiff and the Nationwide Class Members  
25 because they would not have purchased the Products if the true facts were known.

26 151. Because Defendants' retention of the non-gratuitous benefits conferred on them by  
27 Plaintiff and the Nationwide Class Members is unjust and inequitable, Defendants have been  
28 unjustly enriched in an amount to be determined at trial.



- 1 (d) For compensatory, statutory, and punitive damages in amounts to be determined by the  
2 Court and/or jury;
- 3 (e) For prejudgment interest on all amounts awarded;
- 4 (f) For an order of restitution and all other forms of equitable monetary relief;
- 5 (g) For injunctive relief as pleaded or as the Court may deem proper; and
- 6 (h) For an order awarding Plaintiff and the Class and Subclass their reasonable attorneys'  
7 fees and expenses and costs of suit.

8 **JURY TRIAL DEMANDED**

9 Pursuant to Federal Rule of Civil Procedure 38(b), Plaintiff demands a trial by jury of any and  
10 all issues in this action so triable as of right.

11  
12  
13 Dated: October 2, 2024

**BURSOR & FISHER, P.A.**

14 By: /s/ Brittany S. Scott  
Brittany S. Scott

15  
16 L. Timothy Fisher (State Bar No. 191626)  
Brittany S. Scott (State Bar No. 322946)  
17 1990 North California Blvd., 9th Floor  
Walnut Creek, CA 94596  
18 Telephone: (925) 300-4455  
Facsimile: (925) 407-2700  
19 E-mail: ltfisher@bursor.com  
bscott@bursor.com

20  
21 *Attorneys for Plaintiff*

# ClassAction.org

This complaint is part of ClassAction.org's searchable class action lawsuit database and can be found in this post: [CVS Lawsuit Alleges Bandages Contain Dangerous 'Forever Chemicals'](#)

---